Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.
NICE backs NHS use of Lilly’s Olumiant in eczema
3rd March 2021
Eli Lilly’s Olumiant has received a UK National Health and Care Excellence (NICE) recommendation for the treatment of moderate-to-severe atopic dermatitis (atopic eczema) in adults.
NICE has backed use of Olumiant (baricitinib) for patients whose disease has not responded to at least one systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil or where these are not suitable.
Lilly agreed a confidential commercial agreement with NICE, meaning the NHS will receive Olumiant at a discounted price.
Olumiant is an oral JAK inhibitor that acts as an immunosuppressant and blocks the action of JAK1 and JAK2. These enzymes play a key role in the process of inflammation and inflammatory diseases like atopic dermatitis.
p 0.05) between reduced
C. acnes bacteria and improvement in acne occurrence, and overall skin health. The randomized, controlled trial tested for three end goals: if phage reduced
C. acnes on the skin; if the
C. acnes reduction resulted in blemish control; and if this balancing of the microbiome made skin healthier.
Ninety subjects between the ages of 12 and 35 participated for eight weeks to compare the acne prevalence of skin treated with Phyla s Phortify Probiotic Serum containing phage to a placebo group of skin not treated with phage. After eight weeks, subjects treated with phage showed improved Investigator Global Assessment (IGA) scores, compared with the placebo arm (